Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Generalized Anxiety: later-stage trial registry
2 of 4 indexed Generalized Anxiety trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Generalized Anxiety: 4 US clinical trials tracked, 2 recruiting.
Generalized Anxiety is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is ProofPilot, running 1 of these trials.
Enrollment posture brief
Registry condition generalized-anxiety
OPEN 2 | RECR 50% | LATE 3 | EARLY 0 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Generalized Anxiety lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Generalized Anxiety on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Generalized Anxiety is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
Bradley Hospital
NCT06934525
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Otsuka Pharmaceutical Development & Commercialization
NCT06973577
Brain Stimulation & Generalized Anxiety Study
ProofPilot
NCT04751864
An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder
Sanofi
NCT00390533
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Generalized Anxiety records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Generalized Anxiety trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Generalized Anxiety page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Generalized Anxiety trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- ProofPilot sponsors the most Generalized Anxiety trials on record, review their full trial history before evaluating a specific study. See ProofPilot's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Generalized Anxiety condition card totals 4 registered trials; most-linked intervention Saredutant; top US site state Rhode Island. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.